Atlas Trials

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

Clinical trial NCT06178445 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06178445
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract CancerHER2 Gene MutationHER2
Start date
2024-04-17
Primary completion
2026-12-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.